Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:300204'
s Operating Margin % Range Over the Past 10 Years
Min: -98.18 Med: -23.06 Max: 18.67
Current: -39.24
SZSE:300204's Operating Margin % is ranked better than 57.02% of 940
companies
in the Biotechnology industry
Industry Median: -86.55
vs SZSE:300204: -39.24
Staidson (Beijing) Biopharmaceuticals Co Ltd had lost money in 92% of the time over the past 12quarters.
Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Staidson (Beijing) Biopharmaceuticals Co Operating Margin % Related Terms
Staidson (Beijing) Biopharmaceuticals Co Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staidson (Beijing) Biopharmaceuticals Co Operating Margin % Chart
Staidson (Beijing) Biopharmaceuticals Co Annual Data
SZSE:300204 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Staidson (Beijing) Biopharmaceuticals Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Staidson (Beijing) Biopharmaceuticals Co Operating Margin % vs Biotechnology Industry
Staidson (Beijing) Biopharmaceuticals Co Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) has a Operating Margin % of -11.74% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Staidson (Beijing) Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #404 out of 940 companies in the Biotechnology industry, placing it in the top 43%.
Is Staidson (Beijing) Biopharmaceuticals Co's Operating Margin % too high?
Staidson (Beijing) Biopharmaceuticals Co's current Operating Margin % is -11.74%. Based on the distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #404 out of 940 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Staidson (Beijing) Biopharmaceuticals Co has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Staidson (Beijing) Biopharmaceuticals Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Staidson (Beijing) Biopharmaceuticals Co ranks #404 out of 940 companies for Operating Margin %. This puts Staidson (Beijing) Biopharmaceuticals Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Staidson (Beijing) Biopharmaceuticals Co and its competitors. Staidson (Beijing) Biopharmaceuticals Co's current Operating Margin % is -11.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Staidson (Beijing) Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.41, compared to a current price of ¥24.34 — trading 451.9% above its estimated fair value. The current Operating Margin % is -11.74%. Staidson (Beijing) Biopharmaceuticals Co's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204), the current Operating Margin % is -11.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Overvalued in 2026?
Based on GuruFocus' analysis, Staidson (Beijing) Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥24.34 is trading 451.9% above its estimated GF Value™ of ¥4.41.
GuruFocus considers Staidson (Beijing) Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for SZSE:300204:
Operating Margin %: -11.74%
GF Value™: ¥4.41 vs. price of ¥24.34 (451.9% above fair value)
No single metric tells the full story. See the SZSE:300204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Staidson (Beijing) Biopharmaceuticals Co Business Description
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
37GF Score
Get the complete analysis for SZSE:300204
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300204 has been successfully added to your 
